Holen Sie sich die Stockscreener-App
7.65
2.96%
0.22
Handel nachbörslich:
7.70
0.05
+0.65%
Evolus Inc Aktie (EOLS) Neueste Nachrichten
Brady Stewart Bought 59% More Shares In Evolus - simplywall.st
Evolus Submits Evolysse Sculpt for FDA Approval, Expanding HA Dermal Filler Portfolio - Dermatology Times
Evolus submits Evolysse premarket approval application to FDA - TipRanks
Evolus submits final FDA application for mid-face volume filler - Investing.com
Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for Evolysse?? Sculpt Injectable Hyaluronic Acid Gel Product - MarketScreener
Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for Evolysse™ Sculpt Injectable Hyaluronic Acid Gel Product - Business Wire
Evolus plunges after Q2 miss, guidance cut; Needham downgrades - MSN
Director’s Bold Move: Major Stock Purchase Signals Confidence in Evolus - TipRanks
Evolus Sees Aesthetic Market Slowing After Q2 Miss - Orange County Business Journal
Is Evolus Inc. stock technically oversold2025 Trading Volume Trends & Low Drawdown Momentum Trade Ideas - thegnnews.com
Is Evolus Inc. Forming a Consolidation BaseJuly 2025 Recap & Trade Opportunity Analysis - metal.it
Live Scanner Shows Breakout on Evolus Inc.Jobs Report & Verified High Yield Trade Plans - 선데이타임즈
Evolus announces commercial launch of Evolysse - MSN
Midday Stock Roundup: ICU Medical Soars, Willdan Group Down - Orange County Business Journal
Is This the Dip to Buy in Evolus Inc.July 2025 Pullbacks & Capital Protection Trade Alerts - metal.it
Resistance Break Could Fuel Evolus Inc. Rally2025 Risk Factors & High Accuracy Swing Entry Alerts - classian.co.kr
Evolus Q2 2025: Unpacking Contradictions in Toxin Demand, Evolysse Launch, and Consumer Sentiment - AInvest
Evolus, Inc. shares rise 11.53% intraday after reporting inducement grants to new employees. - AInvest
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
How liquid is Evolus Inc. stockNext Day Profit Stock Signals - newsyoung.net
Analysts Just Slashed Their Evolus, Inc. (NASDAQ:EOLS) EPS Numbers - simplywall.st
Evolus (EOLS): Navigating Earnings Revisions and Long-Term Potential in the Aesthetic Medicine Sector - AInvest
Evolus, Inc. Sees Significant Downgrades to Consensus EPS Estimates - AInvest
The Consensus EPS Estimates For Evolus, Inc. (NASDAQ:EOLS) Just Fell Dramatically - Yahoo Finance
The recent earnings and revenue miss by Evolus EOLS -2.80% (EOLS) has sent shockwaves through the aesthetic medicine sector, with sharp downward revisions in analyst expectations raising questions about the company's long-term viability. Q2 2025 res - AInvest
When Will Evolus, Inc. (NASDAQ:EOLS) Turn A Profit? - 富途牛牛
Evolus, Inc. Faces Financial Uncertainty Due to Consumer Spending Risks and Economic Volatility - AInvest
Evolus Receives Buy Rating from Leerink Partners - AInvest
Evolus, Inc. Advances Safety Study of NUCEIVA for Glabellar Lines - TipRanks
A Quick Look at Today's Ratings for Evolus(EOLS.US), With a Forecast Between $18 to $20 - 富途牛牛
Evolus, Inc. (NASDAQ:EOLS) Q2 2025 Earnings Call Transcript - Insider Monkey
Evolus, Inc. Faces Financial Instability Amid Economic Uncertainty and Consumer Spending Risks - TipRanks
Evolus Q2 Earnings: Mixed Sentiments and Strategic Goals for Growth - AInvest
Evolus Maintains Buy Rating Amid Market Challenges Despite Reset in 2025 Revenue Guidance - AInvest
Evolus, Inc. (EOLS) Reports Q2 Loss, Lags Revenue Estimates - MSN
Evolus, Inc. Earnings Call: Mixed Sentiments and Strategic Goals - TipRanks
Evolus Appoints New Principal Financial Officer - MSN
Evolus 2025 Q2 Earnings Misses Targets, Net Loss Widens by 51% - AInvest
Evolus stock down on Q2 miss; Needham downgrades (EOLS:NASDAQ) - Seeking Alpha
Evolus, Inc. shares fall 30.53% intraday after disappointing Q2 earnings and lowered 2025 sales target. - AInvest
Evolus Sees Steady Gains And Eyes Profit Next Year - Finimize
Evolus Reports Q2 Revenue of $69.4mln, Misses Estimates by 15.4%, Lowers Full-Year Guidance - AInvest
Evolus stock price target lowered to $20 by H.C. Wainwright on market headwinds - Investing.com Canada
Evolus price target lowered to $18 from $21 at BTIG - TipRanks
Evolus: HC Wainwright Maintains Buy, PT Down to $20 from $27 - AInvest
Evolus stock price target lowered to $18 at BTIG on Q2 revenue miss By Investing.com - Investing.com South Africa
Evolus stock price target lowered to $18 at BTIG on Q2 revenue miss - Investing.com India
Evolus Stock Plunges 25.14% on Disappointing Earnings - AInvest
Evolus Q2 2025 slides: Filler launch drives market expansion despite earnings miss - Investing.com Nigeria
Evolus, Inc. Reports Q2 2025 Financial Results - TipRanks
Evolus outlines $700M 2028 revenue target and cost realignment amid market softness - MSN
Evolus Reports Second Quarter 2025 Financial Results and Provides Business Updates - BioSpace
Evolus, Inc. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:EOLS) - Seeking Alpha
0.07%
0.62%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):